-
Crovalimab Injection Approved for Marketing by China NMPA
2024-02-07
Recently, the Crovalimab Injection (trade name: 派圣凯/Piasky) of Roche Pharma (Schweiz) AG was approved for marketing by China NMPA through the priority review and approval procedures. It is indicated for use in adults and adolescents (≥12 years old) with paroxysmal nocturnal hemoglobinuria who have not received complement inhibitor therapy.
-
IFI44L Gene Methylation Detection Kit (PCR-Melting Curve Method) Approved for Marketing
2024-02-06
Recently, the application for registration of innovative product "IFI44L Gene Methylation Detection Kit (PCR-Melting Curve Method)" of ShenZhen Sciarray Biotechnology Co., Ltd. was approved by China NMPA.
-
TCM has role in treating respiratory symptoms: Expert
2024-02-02
Traditional Chinese medicine has a distinctive advantage in coping with the wave of respiratory illnesses that has struck China this winter, according to a senior TCM expert.
-
Tegileridine Fumarate Injection Approved for Marketing by China NMPA
2024-01-31
Recently, the Category 1 innovative product Tegileridine Fumarate Injection (trade name: 艾苏特) of Jiangsu Hengrui Pharmaceuticals Co., Ltd. was approved for marketing by China NMPA. It is indicated for moderate to severe pain after abdominal surgery.
-
Innovative TCM Ercha Shangqing Wan approved for marketing
2024-01-24
Recently, the Category 1.1 innovative traditional Chinese medicine (TCM) Ercha Shangqing Wan of Hubei Qijin Pharmaceutical Co Ltd was approved for marketing by China's National Medical Products Administration.
-
China's TCM institutions provide diagnoses, treatment to 1.28 bln people in 2023
2024-01-23
Traditional Chinese medicine (TCM) health care institutions provided diagnoses and treatment to an estimated 1.28 billion people across China in 2023, according to a national TCM meeting that opened on Monday.
